Related Experiment Video

Updated: Jul 17, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Uncovering the evidence frontier beyond the lipid-lowering effects of PCSK9 inhibitors in heart transplantation

Fariba Yazdanpanah1, Gilbert Ramirez2

  • 1Department of General Preventive Medicine and Public Health, The University of Texas Health Science Center at Tyler, Texas, USA.

The American Journal of the Medical Sciences
|July 15, 2026
PubMed

Insights

Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) show promise in managing cardiac allograft vasculopathy (CAV) after heart transplants. Emerging research suggests PCSK9i may also offer benefits beyond lipid reduction, potentially aiding transplant tolerance.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Cardiac allograft vasculopathy (CAV) is a primary long-term complication following heart transplantation (HTx).
  • Dyslipidemia significantly contributes to CAV development, with statins being the current standard therapy but often facing limitations.
  • Alternative lipid-lowering strategies are needed to improve outcomes in HTx recipients.

Purpose of the Study:

  • To review the emerging role of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in managing CAV.
  • To explore the potential of PCSK9i in improving lipid profiles and slowing CAV progression.
  • To investigate novel, lipid-lowering-independent mechanisms of PCSK9i in heart transplantation.

Main Methods:

  • Scoping review of existing literature on PCSK9i in the context of heart transplantation and CAV.
  • Analysis of preclinical data from murine heterotopic heart transplant models.

Main Results:

  • PCSK9i demonstrate significant positive effects on lipid profiles, particularly reducing low-density lipoprotein cholesterol (LDL-c), which may help slow CAV progression.
  • Preclinical studies suggest alirocumab (a PCSK9i) may offer protection against transplant rejection through mechanisms independent of its lipid-lowering effects.
  • Potential immunomodulatory effects, possibly via modulation of hepatic immune responses, are indicated.

Conclusions:

  • PCSK9i represent a promising alternative or adjunctive therapy for managing dyslipidemia and potentially CAV in heart transplant recipients.
  • Novel immunomodulatory properties of PCSK9i, independent of lipid reduction, warrant further investigation in clinical settings.
  • Future research should focus on elucidating the full therapeutic potential of PCSK9i in heart transplantation, including their impact on immune responses.

Keywords:
Evidence frontierHeart transplantPCSK9 InhibitorsScoping review

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...